Total Payments
$371,430
2024 Payments
$31,859
Companies
54
Transactions
807
Medicare Patients
1,933
Medicare Billing
$215,020
Payment Breakdown by Category
Other$281,988 (75.9%)
Consulting$45,050 (12.1%)
Travel$22,634 (6.1%)
Food & Beverage$21,684 (5.8%)
Education$74.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $264,498 | 95 | 71.2% |
| Consulting Fee | $45,050 | 15 | 12.1% |
| Travel and Lodging | $22,634 | 116 | 6.1% |
| Food and Beverage | $21,684 | 565 | 5.8% |
| Honoraria | $17,490 | 9 | 4.7% |
| Education | $74.46 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $153,369 | 252 | $0 (2024) |
| Gilead Sciences, Inc. | $55,874 | 83 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $47,466 | 33 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $41,876 | 68 | $0 (2018) |
| Intercept Pharmaceuticals, Inc. | $15,223 | 42 | $0 (2024) |
| Madrigal Pharmaceuticals | $9,493 | 12 | $0 (2024) |
| Shire North American Group Inc | $7,256 | 17 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6,209 | 52 | $0 (2024) |
| Dova Pharmaceuticals | $5,665 | 7 | $0 (2019) |
| Exact Sciences Corporation | $4,665 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,859 | 89 | Gilead Sciences, Inc. ($12,202) |
| 2023 | $49,337 | 88 | Mallinckrodt Hospital Products Inc. ($15,939) |
| 2022 | $63,291 | 102 | ABBVIE INC. ($22,176) |
| 2021 | $35,270 | 59 | AbbVie Inc. ($13,964) |
| 2020 | $11,139 | 27 | Intercept Pharmaceuticals, Inc. ($6,314) |
| 2019 | $61,409 | 120 | AbbVie, Inc. ($45,996) |
| 2018 | $79,914 | 203 | AbbVie, Inc. ($43,382) |
| 2017 | $39,213 | 119 | AbbVie, Inc. ($16,470) |
All Payment Transactions
807 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $143.82 | General |
| Category: Immunology | ||||||
| 11/25/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $26.82 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/20/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| Category: HCV | ||||||
| 11/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $109.09 | General |
| Category: Gastroenterology | ||||||
| 11/18/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $112.57 | General |
| Category: HCV | ||||||
| 11/14/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/14/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $130.49 | General |
| Category: LIVER DISEASE | ||||||
| 11/13/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/07/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Lilly USA, LLC | OMVOH (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| Category: HCV | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $29.80 | General |
| Category: HCV | ||||||
| 10/29/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $39.36 | General |
| Category: Rare Disease | ||||||
| 10/28/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $93.45 | General |
| Category: LIVER DISEASE | ||||||
| 10/26/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | Cash or cash equivalent | $38.61 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Immunology | ||||||
| 10/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $272.96 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 404 | 425 | $248,117 | $47,212 |
| 2022 | 12 | 457 | 497 | $257,971 | $51,433 |
| 2021 | 12 | 586 | 633 | $326,675 | $67,414 |
| 2020 | 12 | 486 | 571 | $230,346 | $48,961 |
Total Patients
1,933
Total Services
2,126
Medicare Billing
$215,020
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 69 | 69 | $65,067 | $14,358 | 22.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 36 | 36 | $26,892 | $6,484 | 24.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 21 | 22 | $20,746 | $4,527 | 21.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 49 | 49 | $29,400 | $2,915 | 9.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 45 | $9,450 | $2,799 | 29.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 32 | 32 | $25,376 | $2,493 | 9.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $11,952 | $2,305 | 19.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $8,000 | $2,047 | 25.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $8,814 | $1,942 | 22.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 23 | 23 | $6,808 | $1,504 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 16 | $6,272 | $1,488 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 23 | $6,348 | $1,424 | 22.4% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $6,936 | $1,196 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 16 | $7,056 | $1,008 | 14.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 15 | 15 | $9,000 | $724.36 | 8.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 54 | 54 | $50,922 | $10,954 | 21.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 50 | 51 | $20,400 | $5,456 | 26.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 26 | 26 | $19,422 | $4,779 | 24.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 54 | 81 | $17,010 | $4,556 | 26.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 34 | 34 | $26,962 | $3,871 | 14.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 18 | 18 | $16,974 | $3,653 | 21.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Office | 2022 | 17 | 17 | $12,699 | $3,126 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 34 | $13,412 | $2,797 | 20.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $10,140 | $1,940 | 19.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 31 | 31 | $18,600 | $1,938 | 10.4% |
About Dr. Hetal Karsan, MD
Dr. Hetal Karsan, MD is a Gastroenterology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063402881.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hetal Karsan, MD has received a total of $371,430 in payments from pharmaceutical and medical device companies, with $31,859 received in 2024. These payments were reported across 807 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($264,498).
As a Medicare-enrolled provider, Karsan has provided services to 1,933 Medicare beneficiaries, totaling 2,126 services with total Medicare billing of $215,020. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Atlanta, GA
- Active Since 10/24/2005
- Last Updated 01/14/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1063402881
Products in Payments
- Mavyret (Drug) $81,588
- Trulance (Drug) $41,876
- Epclusa (Drug) $41,216
- MAVYRET (Drug) $41,215
- TERLIVAZ (Drug) $29,732
- OCALIVA (Drug) $10,373
- REZDIFFRA (Drug) $9,400
- Viekira (Drug) $7,832
- Vemlidy (Drug) $7,725
- XIFAXAN (Drug) $6,186
- Doptelet (Drug) $5,665
- Cologuard Collection Kit (Device) $4,539
- Mytesi (Drug) $4,303
- CREON (Drug) $3,530
- CUVRIOR (Drug) $3,172
- IBSRELA (Drug) $2,484
- Wako HCC Biomarker(s) DCP and AFP-L3 (Device) $846.65
- Livdelzi (Drug) $800.00
- DUPIXENT (Biological) $530.32
- LINZESS (Drug) $503.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Atlanta
Douglas Wolf, Md, MD
Gastroenterology — Payments: $893,748
Gastroenterology $893,748
Enrique Martinez, Md, MD
Gastroenterology — Payments: $691,094
Gastroenterology $691,094
Dr. Kavita Kongara, M.d, M.D
Gastroenterology — Payments: $576,854
Gastroenterology $576,854
Girish Anand, M.d, M.D
Gastroenterology — Payments: $482,731
Gastroenterology $482,731
Dr. Norman Gitlin, Md, MD
Gastroenterology — Payments: $440,956
Gastroenterology $440,956
Dr. Marc Sonenshine, Md, MD
Gastroenterology — Payments: $311,059
Gastroenterology $311,059